TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9385471

Group type: EXPERIMENTAL
Intervention: Pre-eclamptic patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normotensive pregnant controls
Number of subjects: 2
Study: 8031400

Group type: EXPERIMENTAL
Intervention: Heated humidifier on the inspiratory limb of the breathing circuit (39 degrees C, 90% relative humidity)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No heated humidifier (abdominal operations)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No heated humidifier (limb operations)
Number of subjects: 43
Study: 3230459

Group type: EXPERIMENTAL
Intervention: Residents who audited their own charts for 1985 influenza vaccination ordering
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Residents who audited their own charts for 1985 screening mammography ordering
Number of subjects: 3

Group type: COMPARATOR
Intervention: Passive receipt of results (control group)
Number of subjects: 3
Study: 31082824

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) confined to the culprit lesion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culprit lesion only PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary radial access for PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culprit lesion only PCI in multivessel disease
Number of subjects: 0
Study: 27693921

Group type: EXPERIMENTAL
Intervention: MOV
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 52

Group type: COMPARATOR
Intervention: CON
Number of subjects: 52
Study: 26135803

Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 or 1.5 mg three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat (maximum 2.5 mg three times daily) in PATENT-2
Number of subjects: 0
Study: 23090499

Group type: EXPERIMENTAL
Intervention: Induction therapy with all-trans retinoic acid and TAD (6-thioguanine, cytarabine, daunorubicin)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: TAD-HAM induction (high dose cytarabine, mitoxantrone)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Non-eligible patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Study patients
Number of subjects: 91
Study: 21985684

Group type: EXPERIMENTAL
Intervention: ePsychNurse.Net (eLearning course)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Education as usual (control)
Number of subjects: 158
Study: 17961576

Group type: EXPERIMENTAL
Intervention: Soy supplementation (52 g of soy protein containing 112 mg of isoflavones) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Equol producers (prior to soy supplementation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-equol producers (prior to soy supplementation)
Number of subjects: 40
Study: 17132972

Group type: EXPERIMENTAL
Intervention: Tramiprosate (50, 100, or 150 mg twice daily for 12 weeks)
Number of subjects: 24
Study: 14630680

Group type: EXPERIMENTAL
Intervention: Chemotherapy (more intensive in GELA group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Surgical resection plus chemotherapy (GELD group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Chemotherapy alone (GELA group)
Number of subjects: 44
Study: 12835883

Group type: COMPARATOR
Intervention: Sucralfate 3 g in 15 ml suspension enema
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Mesalazine 4 g gel enema
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg foam enema
Number of subjects: 134
Study: 10389782

Group type: EXPERIMENTAL
Intervention: midazolam 0.5 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 8540847

Group type: EXPERIMENTAL
Intervention: Foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at 120 mg/kg per day
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combination therapy: induction with the other drug for 2 weeks followed by maintenance therapy with both drugs (ganciclovir at 5 mg/kg per day and foscarnet at 90 mg/kg per day)
Number of subjects: 279
Study: 1902405

Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy (both t-PA and urokinase)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Aggressive catheterization strategy
Number of subjects: 575
Study: 6201270

Group type: EXPERIMENTAL
Intervention: ACHM plus amphotericin B (AMB)
Number of subjects: 37

Group type: COMPARATOR
Intervention: ACHM
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ACHM plus AMB
Number of subjects: 37
Study: 3094807

Group type: EXPERIMENTAL
Intervention: Non-mydriatic retinal photography
Number of subjects: 62
Study: 29166666

Group type: EXPERIMENTAL
Intervention: Active Compression Brace (ACB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25444793

Group type: COMPARATOR
Intervention: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine (5 μg, 15 μg, 50 μg, and 150 μg doses)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intramuscular bivalent norovirus virus-like particle (VLP) vaccine
Number of subjects: 4
Study: 23240761

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low TFMP group (no intervention specified)
Number of subjects: 66
Study: 21663486

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 high dose (17.2 billion CFU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019 low dose (1.8 billion CFU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17659770

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 4 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 24 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 37 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 4 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 24 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 37 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PF) at 60 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: RelyX Unicem (RU) at refrigerator temperature
Number of subjects: 40
Study: 17238412

Group type: EXPERIMENTAL
Intervention: Propbank-based Machine Learning (ML) for annotating abstracts of Randomized Controlled Trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-domain (WSJ/WSJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-domain (WSJ/medical abstract)
Number of subjects: 0
Study: 15364434

Group type: EXPERIMENTAL
Intervention: Vaccination against hepatitis B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 11194527

Group type: EXPERIMENTAL
Intervention: Lean fish diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nonfish diet (beef, pork, veal, eggs and milk)
Number of subjects: 11
Study: 9024371

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 micrograms/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (nebulised salbutamol at 2.5 mg or 5.0 mg, depending on age)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 8295467

Group type: EXPERIMENTAL
Intervention: Active laser treatment (1.2 J/point)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Inactive laser treatment (0 J/point)
Number of subjects: 33
Study: 2950179

Group type: EXPERIMENTAL
Intervention: Sunscreen agent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Base used in sunscreen preparation
Number of subjects: 12
Study: 29498748

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (Present in the Now - PIN)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cognitive activity
Number of subjects: 36
Study: 27571499

Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 0
Study: 26714891

Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Self-help attention control
Number of subjects: 166
Study: 23884439

Group type: EXPERIMENTAL
Intervention: High ERCC1 expression
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Performance status ≥ 1
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Number of metastatic sites ≥ 2
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Recurrent disease (versus unresectable)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Molecular factors (ERCC1, thymidylate synthase, dihydropyrimidine dehydrogenase, and others)
Number of subjects: 445
Study: 20674829

Group type: EXPERIMENTAL
Intervention: Combination azelastine and fluticasone nasal spray
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 610
Study: 18320956

Group type: EXPERIMENTAL
Intervention: Voice simulation experience during orientation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Orientation without voice simulation experience
Number of subjects: 94
Study: 16600232

Group type: EXPERIMENTAL
Intervention: Acupuncture on the day of embryo transfer (ET) (ACU 1 group)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Acupuncture on the day of ET and again 2 days later (ACU 2 group)
Number of subjects: 273

Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 273
Study: 14522298

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% applied in 0.1 mL drops 3 times in the 30 minutes before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% applied in 0.1 mL drops 6 times in the 60 minutes before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both regimens of bupivacaine 0.75%
Number of subjects: 40
Study: 11089660

Group type: EXPERIMENTAL
Intervention: Influenza A outbreak in Building A
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Influenza A outbreak in Building B
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Influenza A outbreak in Building C
Number of subjects: 721
Study: 9739895

Group type: EXPERIMENTAL
Intervention: Pristinamycin (1 g b.i.d. for 10 days)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Oxacillin (1 g b.i.d. for 10 days)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 293
Study: 8257472

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 925

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 925

Group type: COMPARATOR
Intervention: Early amniotomy and Conservative management
Number of subjects: 925
Study: 3516619

Group type: COMPARATOR
Intervention: Conventional treatment with azathioprin and steroids (Group A)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG) for three weeks plus azathioprin and steroids (Group B)
Number of subjects: 141

Group type: COMPARATOR
Intervention: ALG-azathioprin-steroid administration for a mean of nine days followed by ciclosporin (Group C)
Number of subjects: 141
Study: 31252303

Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 29165732

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26246320

Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (high scores on the healthy DP) with low energy intake (less than the median)
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Western dietary pattern
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern (high scores on the healthy DP) with high energy intake (greater than or equal to the median)
Number of subjects: 2796
Study: 22946618

Group type: EXPERIMENTAL
Intervention: Bonded hygienic expanders
Number of subjects: 22

Group type: COMPARATOR
Intervention: Banded hyrax expanders
Number of subjects: 22
Study: 21518946

Group type: EXPERIMENTAL
Intervention: Varenicline for 4 weeks before the target quit date (TQD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo for 3 weeks before the TQD, followed by varenicline for 1 week before the TQD
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Varenicline for 4 weeks before the TQD
Number of subjects: 101
Study: 19531608

Group type: EXPERIMENTAL
Intervention: Bilateral training (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unilateral training (n=12)
Number of subjects: 24
Study: 16510862

Group type: EXPERIMENTAL
Intervention: Intensified, multicomponent geriatric treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 174
Study: 14640836

Group type: COMPARATOR
Intervention: Auditory interlingual homophones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual lexical decision times for monolingual controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interlingual homophones with auditory counterparts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublexical cues
Number of subjects: 0
Study: 10955790

Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 134

Group type: COMPARATOR
Intervention: sequential methotrexate and 5-fluorouracil (MF)
Number of subjects: 134
Study: 9088820

Group type: EXPERIMENTAL
Intervention: Post-operative oral diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sacral epidural (caudal) block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments together
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8225043

Group type: EXPERIMENTAL
Intervention: Tocolytic and antibiotic therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 81
Study: 3513012

Group type: EXPERIMENTAL
Intervention: Methotrexate and cyclosporine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 93
Study: 31447072

Group type: EXPERIMENTAL
Intervention: AVF surgical creation with placement of the VasQ implant
Number of subjects: 40

Group type: COMPARATOR
Intervention: AVF surgical creation without the implant (control)
Number of subjects: 40
Study: 30013378

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate and 1% tranilast (B/T)
Number of subjects: 4

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate (B)
Number of subjects: 4
Study: 26865350

Group type: EXPERIMENTAL
Intervention: 1% D-3-hydroxybutyrate eye drops
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 25225151

Group type: EXPERIMENTAL
Intervention: Combination of Boswellia serrata L. and Cyperus scariosus L. (2g) plus pelvic floor muscle training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus pelvic floor muscle training
Number of subjects: 60
Study: 21887727

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Adalimumab (both dosing regimens)
Number of subjects: 778
Study: 20134178

Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine with 20 microg fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8 mg hyperbaric bupivacaine with 20 microg fentanyl
Number of subjects: 60
Study: 16973987

Group type: EXPERIMENTAL
Intervention: Combination of montelukast and salmeterol
Number of subjects: 192
Study: 15808137

Group type: EXPERIMENTAL
Intervention: Comprehensive education program encouraging providers to lengthen return visit interval
Number of subjects: 0
Study: 12225329

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC) in combination with IFN-alpha-2b, 3 MIU, three times weekly via subcutaneous injection, with HDC doses of 1 mg either once a day, three times a week; once a day, five times a week; twice a day, three times a week; or twice a day, five times a week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDC + IFN-alpha-2b
Number of subjects: 0
Study: 12623386

Group type: COMPARATOR
Intervention: Stenting (2 vessel disease)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Stenting (3 vessel disease)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Stenting (2 vessel disease, low-cost estimate)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Stenting (3 vessel disease, low-cost estimate)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: CABG (Control)
Number of subjects: 1205
Study: 9799034

Group type: EXPERIMENTAL
Intervention: Captopril (100 mg daily for 6 months)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Doxazosin (9 mg daily for 6 months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 33
Study: 1989962

Group type: EXPERIMENTAL
Intervention: Monthly written reports
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oil-and-tissue method
Number of subjects: 32

Group type: COMPARATOR
Intervention: Retrospective reporting
Number of subjects: 32
Study: 6638443

Group type: EXPERIMENTAL
Intervention: Selective extradural analgesia maintained throughout labour (Group B)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Selective extradural analgesia allowed to wear off (Group A)
Number of subjects: 2
Study: 30866872

Group type: EXPERIMENTAL
Intervention: Multi-component workplace intervention (height-adjustable workstations, emails, education and training sessions, support from team leaders and a workplace champion)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Multi-component workplace intervention
Number of subjects: 84
Study: 28327172

Group type: EXPERIMENTAL
Intervention: Guizhifulingwan (GFW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23410231

Group type: EXPERIMENTAL
Intervention: DNG/E2V
Number of subjects: 74

Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 74
Study: 21544071

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg for 7 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg for 7 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20030543

Group type: EXPERIMENTAL
Intervention: Amber lenses (blue-blocking glasses) worn for 3 hours prior to sleep
Number of subjects: 20

Group type: COMPARATOR
Intervention: Yellow-tinted glasses (control group, blocking ultraviolet only) worn for 3 hours prior to sleep
Number of subjects: 20
Study: 17702699

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba treatment (240 mg daily) during the first 12 weeks and supervised exercise training during the second 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment during the first 12 weeks and supervised exercise training during the second 12 weeks
Number of subjects: 22
Study: 15198791

Group type: EXPERIMENTAL
Intervention: Total gangliosides in plasma of advanced ovarian cancer patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total gangliosides in ascitic fluid of advanced ovarian cancer patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total gangliosides from primary ovarian cancer cell lines
Number of subjects: 22
Study: 11723262

Group type: EXPERIMENTAL
Intervention: Zonisamide 400 mg/d
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg/d
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Zonisamide 200 mg/d
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 9160129

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM every 8 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metamizol 2 g IM every 8 hours
Number of subjects: 100
Study: 7964663

Group type: EXPERIMENTAL
Intervention: Left-looking heads
Number of subjects: 241

Group type: COMPARATOR
Intervention: Right-looking heads
Number of subjects: 241

Group type: COMPARATOR
Intervention: Judgments of liking
Number of subjects: 241
Study: 3497108

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 213

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 213
Study: 28652127

Group type: EXPERIMENTAL
Intervention: Combined intervention (written material, self‐completed registration cards, and messages to mobile telephones)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 358
Study: 27930894

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CTrach
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: sILMA
Number of subjects: 120
Study: 24458541

Group type: EXPERIMENTAL
Intervention: Clazosentan
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 22362844

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 19819436

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.35 mg isoflavones/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg isoflavones/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 100
Study: 18502358

Group type: EXPERIMENTAL
Intervention: Dead Space (DS) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nondead Space (NDS) group
Number of subjects: 60
Study: 15644045

Group type: EXPERIMENTAL
Intervention: Single dose of 9 MU interferon-alpha2a followed by weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weekly administration of 180 mug of pegylated interferon-alpha2a/ribavirin for 48 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Noncirrhotic patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 30